Abstract:Immune-based therapeutic approaches for IBD, including anti-TNF therapy, have shown significant success during the last decade. Nevertheless, many patients are not responsive to these therapies and suffer from severe side effects. Therefore, an increased understanding of the fundamental immune mechanisms controlling gut inflammation is critical for the rational design and development of more effective therapies of IBD. Innate lymphoid cells (ILCs) have recently emerged as key players in regulating the balance between protective immunity and immunopathology at mucosal surfaces. However, the cellular and molecular pathways that control crosstalk between ILCs and intestinal epithelial cells during inflammation remain poorly understood. Our recent study revealed that Lymphotoxin (LT), a member of TNF superfamily of cytokines, produced by RORgt+ ILCs in the gut is critical for protection against the mucosal bacterial pathogen Citrobacter rodentium. In the present study, we aimed to determine how LT signaling controls ILCs to regulate the intestinal inflammation. An acute mouse model of IBD induced by dextran sodium sulfate (DSS) was used. WT and LT-beta receptor (LTbR)-deficient mice were treated with 3.5% DSS in drinking water for 5 days followed by normal water thereafter. Our data show that LTbR signaling is essential for protection and recovery from DSS-induced colitis. LTbR deficient mice failed to upregulate IL-22 in the colon and succumbed rapidly after DSS administration. By using RORgt-GFP reporter mice and cell sorting approach we found the impaired IL-22 production by distinct populations of ILCs in the colon after DSS-induced inflammation. Recent studies indicated a protective role of IL-22 in IBD by enhancing barrier integrity and epithelial innate immunity. We found that reduced IL-22 expression in LTbR-deficient mice was associated with defected mucin genes expression and impaired proliferation of intestinal epithelial cells after DSS-induced injury. Bone marrow transfer experiments revealed that LTbR expression on both bone marrow-derived and radioresistant stromal cells is required for the control of intestinal inflammation. To define which LTbR-expressing cells are essential for protection, we have generated mice with a specific inactivation of LTbR in intestinal epithelial cells, and bone marrow-derived cell populations. These mouse models will help us to further investigate the critical pathways to control intestinal inflammation. Our data indicate that LTbR signaling prevents intestinal inflammation by controlling the IL-22 protection pathway.

A Th17 cell-intrinsic glutathione/mitochondrial-IL-22 axis protects against intestinal inflammation

Correction: RORγt Represses IL-10 Production in Th17 Cells to Maintain Their Pathogenicity in Inducing Intestinal Inflammation

Interleukin-22 protects intestinal stem cells against genotoxic stress

Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft Versus Host Disease.

Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis

Short chain fatty acids regulate T cell metabolism to promote IL-22 production and gut immunity

Attenuation of Experimental Colitis in Glutathione Peroxidase 1 and Catalase Double Knockout Mice through Enhancing Regulatory T Cell Function

Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge

Toll-like receptor 7 protects against intestinal inflammation and restricts the development of colonic tissue-resident memory CD8+ T cells

Spontaneous Colitis in IL-10-deficient Mice Was Ameliorated Via Inhibiting Glutaminase1

Interleukin-22-deficiency and Microbiota Contribute to the Exacerbation of Toxoplasma Gondii-Induced Intestinal Inflammation

Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism

Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology

The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation

Lymphotoxin-Dependent Control of Intestinal Inflammation

Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity

Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity

Interleukin 21 Drives a Hypermetabolic State and CD4+ T-Cell-Associated Pathogenicity in Chronic Intestinal Inflammation

A type 1 immune-stromal cell network mediates disease tolerance and barrier protection against intestinal infection

c-Maf-dependent Treg cell control of intestinal TH17 cells and IgA establishes host–microbiota homeostasis

CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation